Aripiprazole for the Management of Olanzapine-induced Weight Gain

Abstract

Weight gain is an important side eff ect of olanzapine. One therapeutic strategy might be the add-on of aripiprazole, a partial dopaminergic and serotonergic agonist. Here, we report on four patients who experienced a signifi cant reduction of body weight after aripiprazole was added in a mean dose of 13.8 mg / day to the preexisting olanzapine therapy and olanzapine was reduced from a mean dose of 17.5 to 11.3 mg / day. We did not observe signifi cant changes in fasting glucose, triglycerides, and cholesterol. This approach might increase safety, tolerability and patient ' s adherence to olanzapine treatment and should be further evaluated in controlled trials.

Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain

“…The low (10 mg/kg/day) and high (40 mg/kg/day) doses lie in the range of other animal trials with subcutaneaous (Li et al 2005), oral (Inoue et al 1998;Kalinichev et al 2005) (Dr. Kikutichi, personal communication), or intraperitoneal (Cheng et al 2008;Semba et al 1995;Semba et al 1996) routes of application. APZ treatment showed a tendency to induce weight loss in our system (Segnitz et al 2009) in contrast to the animal study of Kalinichev et al (2005) but quite in concert with clinical observations (Englisch et al 2009;Henderson et al 2009). The low expression levels of NR2C and NR2D in frontocortical regions have been reported previously (Goebel and Poosch 1999).…”

Development of a validated HPLC method for simultaneous determination of olanzapine and aripiprazole in human plasma

“…There are many reports in the literature about the combined use of olanzapine and aripiprazole [5][6][7][8][9][10]. As an example, Duggal reported the first case about this combination [5].…”